Recent clinical evidence highlights the practical application of Teplizumab for Type 1 Diabetes in adult patients. A recent study detailed the first Italian experience using this immunotherapy under a compassionate use program. Specifically, researchers focused on three women with Stage 2 disease to evaluate safety and early outcomes outside formal clinical trials.

Real-World Safety of Teplizumab for Type 1 Diabetes

The 14-day treatment course proved overall well-tolerated. Interestingly, although some patients developed transient lymphopenia and mild liver enzyme elevations, these issues resolved without intervention. One patient experienced a mild cytokine-release syndrome but required only supportive care. Furthermore, all participants maintained stable glycemic control and preserved beta-cell function during the 3-month follow-up. These results mirror findings from pivotal trials while confirming feasibility in an academic hospital setting.

Implementing a Multidisciplinary Approach

Successful administration of this immunotherapy requires a structured team. This multidisciplinary group should include endocrinologists, anesthesiologists, and psychologists. Consequently, this approach optimizes patient engagement and manages psychological stress during the 14-day infusion period. Moreover, proper pre-medication and monitoring ensure that clinicians can address side effects immediately. Therefore, integrating diverse specialties remains crucial for the success of disease-modifying therapies in presymptomatic diabetes.

FAQ

Who is eligible for Teplizumab for Type 1 Diabetes?

Clinicians typically recommend Teplizumab for adults and children aged 8 years and older with Stage 2 Type 1 Diabetes. This stage involves the presence of two or more islet autoantibodies and abnormal blood sugar levels without clinical symptoms.

What are the common side effects observed?

Patients often experience a temporary drop in white blood cell counts, mild skin rashes, or cytokine-release syndrome. However, these side effects are usually manageable with standard medical care and resolve shortly after treatment.

How does Teplizumab delay the progression of diabetes?

Teplizumab acts as an anti-CD3 monoclonal antibody. Specifically, it modulates the T-cells responsible for destroying insulin-producing beta cells. By doing so, it buys patients significant time before they require daily insulin therapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

1. Guarnotta V et al. Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients. Diabetes Obes Metab. 2026 Mar 08. doi: 10.1111/dom.70626. PMID: 41796109.


2. Herold KC et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613.


3. FDA. FDA Approves First Drug Can Delay Onset of Type 1 Diabetes. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes.